Novartis sees no 2012 revenue slippage despite Diovan and Tekturna
This article was originally published in Scrip
Novartis believes its sales this year can match those of 2011, despite the expiry of the patent on its best-selling antihypertensive drug Diovan (valsartan) and the unwelcome trial results late last year for the newer antihypertensive Tekturna/Rasilez (aliskiren), which has led to the company advising doctors to avoid using it in certain patients. The upbeat forecast came as the Swiss group reported a 4% increase in fourth-quarter sales to $14.8 billion and a 16% increase in full-year sales to $48.6 billion for 2011.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.